Login
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Nature Medicine, Published online: 29 September 2025; doi:10.1038/s41591-025-03918-x
In the proof-of-concept phase 2 ROME trial, comprehensive genomic profiling followed by molecular tumor board evaluation and randomization of patients with metastatic solid cancer to receive personalized therapy or standard of care led to a significantly higher objective response rate and longer progression-free survival in patients who received personalized therapy.